SCHEMBL5164816

SCHEMBL5164816

CCOP(=O)(OCC)C(F)(F)c1ccc(CN(Cc2ccc(C(F)(F)P(=O)(OCC)OCC)cc2)S(=O)(=O)C=Cc2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 18/20 0.43
HTR5A P47898 1/20 0.42
NR1I2 O75469 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5164809 1.00 PTPN1 (0.43) PTPN1HTR5ANR1I2
SCHEMBL5164825 0.88 PTPN1 (0.39) PTPN1HTR5A
SCHEMBL5165507 0.78 PTPN1 (0.47) PTPN1
SCHEMBL5167236 0.75 PTPN1 (0.47) PTPN1
SCHEMBL5166709 0.74 PYCR1 (0.41) PTPN1NR1I2
SCHEMBL5165292 0.74 PTPN5 (0.44) PTPN1
SCHEMBL21593705 0.73 L3MBTL1 (0.49) HTR5A
SCHEMBL5795784 0.72 PTPN1 (0.48) PTPN1NR1I2
SCHEMBL5179142 0.72 HDAC1 (0.51) PTPN1
SCHEMBL5165954 0.72 PTPN1 (0.53) PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765332-A2 TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-03-28 EP disclosed
US-20060135773-A1 Trisubstituted nitrogen modulators of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US disclosed
WO-2006009876-A2 TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135773-A1 Trisubstituted nitrogen modulators of tyrosine phosphatases PTPA, PTPN1, PTPRS PTPN1 2/4885HTR5A 2178/4885NR1I2 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.